Sorry, you need to enable JavaScript to visit this website.

A Study of Talazoparib in Patients with Breast Cancer That is Advanced or Has Spread

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer (ABRAZO Study)

Category & Conditions: Cancer
Medicine: Talzenna (talazoparib) Identifier (NCT): NCT02034916
Protocol ID: 673-201 (C3441008)
Open Plain Language Summary Result: Click here